Charles Schwab Investment Management Inc Adma Biologics, Inc. Transaction History

Charles Schwab Investment Management Inc

$519 Billion
Q2 2024

A detailed history of Charles Schwab Investment Management Inc transactions in Adma Biologics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 2,152,121 shares of ADMA stock, worth $42.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,152,121

Previous 1,775,120 21.24%

Holding current value

$42.1 Million

Previous $11.7 Million 105.38%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$5.98 - $11.18 $2.25 Million - $4.21 Million	377,001 Added 21.24%	2,152,121 $24.1 Million
Q1 2024 May 08, 2024	BUY	$4.4 - $6.74 $609,034 - $932,930	138,417 Added 8.46%	1,775,120 $11.7 Million
Q4 2023 Feb 06, 2024	BUY	$3.08 - $4.52 $84,259 - $123,653	27,357 Added 1.7%	1,636,703 $7.4 Million
Q3 2023 Nov 08, 2023	BUY	$3.47 - $4.61 $3.61 Million - $4.79 Million	1,039,893 Added 182.61%	1,609,346 $5.76 Million
Q2 2023 Aug 09, 2023	BUY	$3.12 - $4.22 $22,560 - $30,514	7,231 Added 1.29%	569,453 $2.1 Million
Q1 2023 May 11, 2023	BUY	$3.01 - $3.87 $229,398 - $294,940	76,212 Added 15.68%	562,222 $1.86 Million
Q4 2022 Feb 13, 2023	BUY	$2.47 - $3.88 $19,261 - $30,256	7,798 Added 1.63%	486,010 $1.89 Million
Q3 2022 Nov 14, 2022	BUY	$2.03 - $2.86 $1,297 - $1,827	639 Added 0.13%	478,212 $1.16 Million
Q2 2022 Aug 15, 2022	BUY	$1.43 - $2.2 $583,934 - $898,361	408,346 Added 589.87%	477,573 $946,000
Q4 2021 Feb 11, 2022	BUY	$1.09 - $1.66 $75,457 - $114,916	69,227 New	69,227 $98,000
Q3 2021 Nov 16, 2021	SELL	$1.13 - $1.65 $66,587 - $97,229	-58,927 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$1.51 - $2.07 $178,673 - $244,936	-118,327 Reduced 66.76%	58,927 $95,000
Q1 2021 May 17, 2021	BUY	$1.67 - $2.95 $33,812 - $59,728	20,247 Added 12.9%	177,254 $312,000
Q4 2020 Feb 16, 2021	BUY	$1.8 - $2.56 $21,738 - $30,917	12,077 Added 8.33%	157,007 $307,000
Q3 2020 Nov 13, 2020	SELL	$2.04 - $3.74 $17,741 - $32,526	-8,697 Reduced 5.66%	144,930 $347,000
Q2 2020 Aug 14, 2020	SELL	$2.42 - $3.29 $47,497 - $64,572	-19,627 Reduced 11.33%	153,627 $451,000
Q1 2020 May 15, 2020	BUY	$1.5 - $4.59 $89,130 - $272,737	59,420 Added 52.2%	173,254 $499,000
Q3 2019 Nov 08, 2019	BUY	$3.19 - $5.39 $155,206 - $262,245	48,654 Added 74.65%	113,834 $507,000
Q2 2019 Aug 09, 2019	BUY	$3.52 - $5.24 $75,609 - $112,555	21,480 Added 49.15%	65,180 $253,000
Q3 2018 Nov 13, 2018	BUY	$4.39 - $6.85 $36,437 - $56,855	8,300 Added 23.45%	43,700 $272,000
Q2 2018 Aug 08, 2018	BUY	$4.39 - $5.44 $155,406 - $192,576	35,400 New	35,400 $160,000

Others Institutions Holding ADMA

# of Institutions

265

Shares Held

178M

Call Options Held

535K

Put Options Held

21.2K

View Full List

About ADMA BIOLOGICS, INC.

Ticker ADMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 196,356,992
Market Cap $3.84B
Description
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...

More about ADMA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account

Charles Schwab Investment Management Inc Adma Biologics, Inc. Transaction History